← Leaderboards
Paul John Galardy
Mayo Clinic Rochester
$1,616,689
Attributed
$1,616,689
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $327.2K · FY2011–15$500K$375K$250K$125K$0
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$1,616,689 · 1
By mechanism
R01$1,616,689 · 1
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Susan L Slager$16,375,515
- Scott H Kaufmann$29,002,745
- Esteban Braggio$6,330,549
- Shaji Kunnathu Kumar$7,127,192
- Nathan P Staff$5,882,116
Others in their field
Top investigators on “Adult”
- Lawrence Corey · Fred Hutchinson Cancer Center$594,628,824
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$397,114,680
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$388,038,550
- Judith S. Currier · University Of California Los Angeles$251,592,913
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$196,603,707
- Carol Nesel · Westat$188,148,170
Research focus
AdultAccountingBaseB-Cell LymphomasAffectBinding (Molecular Function)BiochemicalBiologyB-LymphocytesB Lymphoid MalignancyB-Cell NeoplasmCancer BurdenCancer TherapyCell DeathCell LineCessation Of LifeChargeChildClinical TrialsComplexDiagnosisDna RepairBortezomibEvent
Grant awards (5)
Exploring the role of the de-ubiquitinase UCH-L1 in B-cell malignancy$327,228
R01 · FY2015 · CA · contact PI
Exploring the role of the de-ubiquitinase UCH-L1 in B-cell malignancy$317,411
R01 · FY2014 · CA · contact PI
Exploring the role of the de-ubiquitinase UCH-L1 in B-cell malignancy$317,594
R01 · FY2013 · CA · contact PI
Exploring the role of the de-ubiquitinase UCH-L1 in B-cell malignancy$327,228
R01 · FY2012 · CA · contact PI
Exploring the role of the de-ubiquitinase UCH-L1 in B-cell malignancy$327,228
R01 · FY2011 · CA · contact PI